Last reviewed · How we verify
MAPROTILINE
Maprotiline is a small molecule drug that targets the alpha-1A adrenergic receptor. It was originally developed and is currently owned by a pharmaceutical company. Maprotiline is used to treat depressive disorder and mixed anxiety and depressive disorder, and was FDA approved in 1980. The drug is now off-patent and has multiple generic manufacturers. Key safety considerations include its long half-life of 51 hours and moderate bioavailability of 68%.
At a glance
| Generic name | MAPROTILINE |
|---|---|
| Drug class | maprotiline |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1980 |
Approved indications
- Depressive disorder
- Mixed anxiety and depressive disorder
Common side effects
Drug interactions
- isocarboxazid
- methylthioninium chloride
- phenelzine
- procarbazine
- selegiline
- tranylcypromine
Key clinical trials
- A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma (PHASE1)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- A Study of Chinese Medicine Treating Depression
- Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAPROTILINE CI brief — competitive landscape report
- MAPROTILINE updates RSS · CI watch RSS